Advaxis to Participate in Five Upcoming Industry Conferences
May 07 2019 - 9:00AM
Business Wire
Advaxis, Inc. (NASDAQ: ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of immunotherapy products, announces
participation in five upcoming industry conferences:
BioNJ 9th Annual BioPartnering Conference
- Date and Time: Wednesday, May 8,
2019 at 2:00pm ET
- Venue: The Palace at Somerset Park
- Gatsby Suite, Somerset, New Jersey
- Presenter: Molly Henderson, Executive
Vice President and Chief Financial Officer
- Presentation: Corporate overview
Frontiers in Cancer Immunotherapy
- Date: Tuesday, May 14, 2019
- Venue: The New York Academy of
Sciences, New York, New York
- Presenter: Robert Petit, Ph.D., Chief
Scientific Officer
- Two Poster Presentations: Safety and
Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in
Cancer Patients; and Effects of ADXS-PSA With or Without
Pembrolizumab on Survival and Antigen Spreading in Metastatic,
Castration-Resistant Prostate Cancer Patients (Results from
KEYNOTE-046)
Immuno-Oncology Xchange
- Date and Time: Wednesday, May 15, 2019
at 12:30pm ET
- Venue: Seaport World Trade Center,
Boston, Massachusetts
- Presenter: Andres A. Gutierrez, M.D.
Ph.D., Chief Medical Officer
- Presentation: Challenges of
First-in-Human Phase I Dose-Escalating Trials in Patients with
Advanced Cancers
BIO International Convention
- Date: June 3-6, 2019
- Venue: Pennsylvania Convention Center,
Philadelphia, Pennsylvania
- Management holding partnering meetings:
Ken Berlin, President and Chief Executive Officer, and Molly
Henderson, Executive Vice President and Chief Financial
Officer
IO Combinations 360°
- Date and Time: June 20-21, 2019 at
12:00pm ET
- Venue: Wyndham Historic District Hotel,
Philadelphia, Pennsylvania
- Presenter: J. Randolph Hecht M.D.,
Professor of Clinical Medicine, David Geffen School of Medicine at
UCLA and Director of the UCLA Gastrointestinal Oncology
Program
- Presentation: A Phase 1 Dose-Escalation
Study of ADXS-NEO Expressing Personalized Tumor Antigens in
Subjects with Advanced Solid Tumors: Updated Results
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of
proprietary Lm-based antigen delivery products. These
immunotherapies are based on a platform technology that utilizes
live attenuated Listeria monocytogenes (Lm) bioengineered to
secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy and are designed to access and direct antigen
presenting cells to stimulate anti-tumor T cell immunity, activate
the immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable T cells to eliminate tumors. Advaxis has
four programs in various stages of clinical development: ADXS-HPV
for cervical cancer; ADXS-NEO, a personalized neoantigen-directed
therapy for multiple cancers; ADXS-503 for non-small cell lung
cancer, from its ADXS-HOT off-the-shelf neoantigen-directed
program; and ADXS-PSA for prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook and YouTube.
Advaxis Forward-Looking Statement
Some of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. The factors that could
cause our actual results to differ materially include: the success
and timing of our clinical trials, including subject accrual; our
ability to avoid any clinical holds and to resolve FDA’s partial
clinical hold; our ability to obtain and maintain regulatory
approval and/or reimbursement of our product candidates for
marketing; our ability to obtain the appropriate labeling of our
products under any regulatory approval; our plans to develop and
commercialize our products; the successful development and
implementation of our sales and marketing campaigns; the size and
growth of the potential markets for our product candidates and our
ability to serve those markets; our ability to successfully compete
in the potential markets for our product candidates, if
commercialized; regulatory developments in the United States and
other countries; the rate and degree of market acceptance of any of
our product candidates; new products, product candidates or new
uses for existing products or technologies introduced or announced
by our competitors and the timing of these introductions or
announcements; market conditions in the pharmaceutical and
biotechnology sectors; our available cash; the accuracy of our
estimates regarding expenses, future revenues, capital requirements
and needs for additional financing; our ability to obtain
additional funding; our ability to obtain and maintain intellectual
property protection for our product candidates; the success and
timing of our preclinical studies including IND-enabling studies;
the timing of our IND submissions; our ability to get FDA approval
for study amendments; the timing of data read-outs; the ability of
our product candidates to successfully perform in clinical trials;
our ability to initiate, enroll, and execute pilots and clinical
trials; our ability to maintain collaborations; our ability to
manufacture and the performance of third-party manufacturers; the
performance of our clinical research organizations, clinical trial
sponsors and clinical trial investigators; our ability to
successfully implement our strategy; and, other risk factors
identified from time to time in our reports filed with
the SEC. Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We
do not intend to update any of these forward-looking statements to
reflect events or circumstances that occur after the date
hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190507005615/en/
Investors:LHA Investor RelationsYvonne Briggs, (310)
691-7100ybriggs@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024